A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors

British Journal of Clinical Pharmacology

Volumn 80, Issue 4, 2015, Pages 662-669

  Cressman, Alex M ^a,b   Macdonald, Erin M ^a   Fernandes, Kimberly A ^a   Gomes, Tara ^a,c,d,e   Paterson, J Michael ^a,c   Mamdani, Muhammad M ^a,c,d,e,f   Juurlink, David N ^a,b,c,d,g  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g Canada   (Canada)

Author keywords

angiotensin converting enzyme inhibitors; clopidogrel; congestive heart failure; mortality; myocardial infarction

Indexed keywords

CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; PERINDOPRIL; RAMIPRIL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE HEART INFARCTION; AGED; ARTICLE; CANADA; CHARLSON COMORBIDITY INDEX; CONTROLLED STUDY; DRUG INTERACTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; VERY ELDERLY; ANALOGS AND DERIVATIVES; CASE CONTROL STUDY; COMBINATION DRUG THERAPY; FACTUAL DATABASE; MYOCARDIAL INFARCTION; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE; HUMANS; LISINOPRIL; MALE; MYOCARDIAL INFARCTION; PERINDOPRIL; PLATELET AGGREGATION INHIBITORS; RAMIPRIL; RECURRENCE; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84942551973     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12682     Document Type: Article

References (35)

1. IMS Institute for Health Informatics. The Use of Medicines in the United States: Review of 2011. Available at https://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII-Medicines-in-U.S-Report-2011.pdf (last accessed 30 May 2014).
2. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E,. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.
3. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97: 2202-12.
4. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ,. AHA/ACC Guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: e344-426.
5. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Kushner FG, Ohman EM, Stevenson WG, Yancy CW,. American College of Cardiology Foundation/American Heart Association Task Force on Practice G. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.
6. Snyder D,. Pediatric Focused Safety Review: Plavix® (clopidogrel) Pediatric Advisory Committee Meeting 2013. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM369698.pdf (last accessed 30 May 2014).
7. Hansen ML, Gislason GH, Kober L, Schramm TK, Folke F, Buch P, Abildstrom SZ, Madsen M, Rasmussen S, Torp-Pedersen C,. Different angiotensin-converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 2008; 65: 217-23.
8. Tu K, Gunraj N, Mamdani M,. Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction? Am J Cardiol 2006; 98: 6-9.
9. Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB,. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy 2013; 33: 210-22.
10. Zhu HJ, Wang X, Gawronski BE, Brinda BJ, Angiolillo DJ, Markowitz JS,. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther 2013; 344: 665-72.
11. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, Axelsson T, Haertter S, Oldgren J, Reilly P, Siegbahn A, Syvanen AC, Wadelius C, Wadelius M, Zimdahl-Gelling H, Yusuf S, Wallentin L,. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 2013; 127: 1404-12.
12. Hagihara K, Kazui M, Kurihara A, Yoshiike M, Honda K, Okazaki O, Farid NA, Ikeda T,. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug metabolism and disposition: the biological fate of chemicals 2009; 37: 2145-52.
13. Brown NJ, Vaughan DE,. Angiotensin-converting enzyme inhibitors. Circulation 1998; 97: 1411-20.
14. Geshi E, Kimura T, Yoshimura M, Suzuki H, Koba S, Sakai T, Saito T, Koga A, Muramatsu M, Katagiri T,. A single nucleotide polymorphism in the carboxylesterase gene is associated with the responsiveness to imidapril medication and the promoter activity. Hypertension research: official journal of the Japanese Society of Hypertension 2005; 28: 719-25.
15. Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS,. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol 2009; 77: 1266-72.
16. Merali Z, Ross S, Pare G,. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact 2014; 29: 143-51.
17. Lewis JP, Horenstein RB, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, Tanner K, Chai S, Bliden KP, Tantry US, Peer CJ, Figg WD, Spencer SD, Pacanowski MA, Gurbel PA, Shuldiner AR,. The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response. Pharmacogenet Genomics 2013; 23: 1-8.
18. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, Malcolm R, Johnson JA, Youngblood GL, Sweet DH, Langaee TY, Markowitz JS,. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008; 82: 1241-8.
19. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, Yan B,. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 2006; 319: 1477-84.
20. Thomsen R, Rasmussen HB, Linnet K, Consortium I,. In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors. Drug metabolism and disposition: the biological fate of chemicals 2014; 42: 126-33.
21. Takahashi S, Katoh M, Saitoh T, Nakajima M, Yokoi T,. Different inhibitory effects in rat and human carboxylesterases. Drug metabolism and disposition: the biological fate of chemicals 2009; 37: 956-61.
22. Zhu HJ, Appel DI, Peterson YK, Wang Z, Markowitz JS,. Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology 2010; 270: 59-65.
23. Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp-Pedersen C, Rasmussen HB, Markowitz JS, Hansen PR,. Clopidogrel bioactivation and risk of bleeding in patients co-treated with ACE inhibitors after myocardial infarction: A proof of concept study. Clin Pharmacol Ther 2014; 96: 713-22.
24. Hux JE, Ivis F, Flintoft V, Bica A,. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002; 25: 512-6.
25. Schultz SE, Rothwell DM, Chen Z, Tu K,. Identifying cases of congestive heart failure from administrative data: a validation study using primary care patient records. Chronic diseases and injuries in Canada 2013; 33: 160-6.
26. Tu K, Campbell NR, Chen ZL, Cauch-Dudek KJ, McAlister FA,. Accuracy of administrative databases in identifying patients with hypertension. Open medicine 2007; 1: e18-26.
27. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 2004; 351: 543-51.
28. Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA,. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 2003; 289: 1652-8.
29. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, Austin PC, Laupacis A, Stukel TA,. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363: 1751-6.
30. Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, Henry DA, Kopp A, Mamdani MM,. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-8.
31. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM,. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354: 1352-61.
32. Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA,. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007; 298: 2634-43.
33. Juurlink D, Preyra C, Croxford R, Chong A, Austin P, Tu J, Laupacis A,. Canadian Institute for Health Information Discharge Abstract Database: a Validation Study. Toronto: Institute for Clinical Evaluative Sciences; 2006.
34. Austin PC, Grootendorst P, Anderson GM,. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007; 26: 734-53.
35. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y,. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412.